pharmaceutical-investing CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection
pharmaceutical-investing CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
pharmaceutical-investing CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
pharmaceutical-investing CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology Annual Meeting
pharmaceutical-investing CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
pharmaceutical-investing CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
African Discovery Group announces signing of Definitive Sales and Purchase Agreement for Butembo Copper Asset in the Democratic Republic of Congo; name change to Copper Intelligence, Inc
Saga Metals Acknowledges U.S. Strategic Critical Minerals Reserve "Project Vault" and Highlights Titanium's Strategic Importance to North American Defense Supply Chains
Blackrock Silver to Present at the Precious Metals and Critical Minerals Virtual Investor Conference on February 10th 2026
